newsfilter
← Latest News
Business Wire·

OS Therapies FDA Meeting Request Granted

Written response-only meeting to align analysis plan of surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung